Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

NCT02663687 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema (HAE)

Interventions

DRUG: Recombinant human C1 esterase inhibitor
DRUG: Placebo
DRUG: SHP623
DRUG: Placebo

Sponsor

Shire